Multiple myeloma, the second most deadly blood cancer,  is a plasma cell dyscrasia that is characterized by abnormal production of monoclonal (M) immunoglobulins (M-Proteins), each consisting of two heavy chains and two light chains (κ and λ).    In most patients with a monoclonal plasma cell disorder, the monoclonal light chains secreted by the clone remain soluble in the bloodstream. However, in some patients, free light chains may infiltrate tissues, inducing a myriad of impairments, forming plaques that may eventually lead to organ failure. This research describes the investigation of a series of biocompatible nanostructures functionalized with anti- κ and anti- λ antibodies for targeted binding with the light chain immunoglobulins.  Further, the functional nanostructures are then evaluated for their ability to inhibit of aggregation of the immunoglobulins into plaque-like networks.

Investigation of nanomaterials for inhibition of amyloid plaque formation in multiple myeloma cancer

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.